I can’t reliably pull the very latest updates right now because my web-access tools are unavailable for this turn. But I can share several recent, sourced items about daraxonrasib (RMC-6236) and its KRAS / pan-RAS target that should help you orient to the current news cycle:
If you tell me what you mean by “latest” (e.g., “past 7 days” vs “past month”) and whether you want clinical-trial news only or also lab/mechanism papers, I can narrow this to a tighter, up-to-date roundup once access to live sources is working again.
Sources:[1][4][7][10]
KRAS mutations, which induce proliferative signaling driving many human cancers, are detectable in a small subset of osteosarcoma patients. The recently developed pan-KRAS inhibitor daraxonrasib, also known as RMC-6236, is capable of targeting a ...
pmc.ncbi.nlm.nih.govA new drug targeting the KRAS mutation is transforming outcomes for pancreatic cancer patients, potentially opening doors for other cancers.
longevitytoday.comDaraxonrasibSearch drug represents a new class of RASSearch term(ON) multi-selective inhibitors designed to target multiple RAS isoforms in their active state. The drug specifically addresses KRAS G12Search term mutations, which are among the most common oncogenic drivers in pancreatic cancerSearch disease. This targeted approach marks a departure from traditional chemotherapy regimens that have shown limited efficacy in the metastatic setting.
trial.medpath.comThe FDA has granted breakthrough therapy designation to daraxonrasib for metastatic pancreatic cancer with KRAS G12 mutations.
rarecancernews.comRevolution Medicines’ daraxonrasib shows promising clinical results for metastatic pancreatic cancer, targeting previously undruggable...
www.chemdiv.comKRAS mutations, which induce proliferative signaling driving many human cancers, are detectable in a small subset of osteosarcoma patients. The recently developed pan-KRAS inhibitor daraxonrasib, also known as RMC-6236, is capable of targeting a wide array of KRAS mutations and shows promise against pancreatic and lung cancers. However, the efficacy and mechanisms of action of daraxonrasib in osteosarcoma (OS) remain unclear. We evaluated the effects of daraxonrasib on the viability,...
journals.plos.orgThe targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to results of a Phase 1/2 trial led by researchers at The University of Texas MD Anderson Cancer Center.
www.eurekalert.org